Top 10 Pain Management Companies

Why Is the Pain Management Market Expanding?

The Pain Management Market reached USD 87.65 billion in 2025 and is projected to grow from USD 91.82 billion in 2026 to approximately USD 139.80 billion by 2035, registering a compound annual growth rate (CAGR) of 4.95% during the 2026–2035 forecast period. Market Research Future (MRFR) identifies the convergence of two structural forces as the primary demand accelerators: an ageing global population generating a persistent chronic pain burden from osteoarthritis, diabetic neuropathy, and post-surgical conditions, and a simultaneous regulatory realignment away from opioid monotherapy toward multimodal analgesia approaches that actively expand the addressable market for non-pharmacological pain relief solutions.

The US CDC's 2022 Clinical Practice Guideline for Prescribing Opioids formally established multimodal analgesia as the first-line standard of care for chronic non-cancer pain, while the European Commission's Pharmaceutical Strategy earmarked EUR 1.2 billion for non-addictive analgesic R&D through 2030, together catalysing the fastest reallocation of commercial pain management investment in a decade.

Drugs are the dominating modality, with an estimated 73.5% of 2025 market value, led by opioid analgesic treatment for cancer and post-surgical pain and an expanding non-narcotic analgesic segment including NSAIDs, CGRP inhibitors and gabapentinoids. The device segment, smaller at about USD 13.5 billion in 2025, is projected to grow at 10.8% CAGR, which is more than twice the overall market rate. This is driven by closed-loop spinal cord stimulators, radiofrequency ablation systems, and high-frequency neuromodulation platforms that offer sustained relief without the risk of pharmacological dependence. The application category of neuropathic pain is leading with a 34.2% revenue share, indicating the global diabetes pandemic affecting more than 537 million adults, whereas the facial pain and migraine segment is growing at 9.4% CAGR on the strength of CGRP inhibitor commercial success.

North America secured about 35.4% of the revenue share in 2025, amounting to USD 31.03 billion. This can be ascribed to the largest commercial insurance ecosystem globally, in addition to the high per-capita expenditure on interventional pain procedures. The Centres for Medicare & Medicaid Services’ (CMS) 2024 reimbursement parity ruling that expanded ambulatory surgical centre eligibility for 14 additional pain procedures will also boost growth.

Asia-Pacific is the fastest-growing region with a projected CAGR of 11.5% through 2035, driven by the allocation of CNY 22 billion to pain-specialty departments in China under the 14th Five-Year Plan, the expansion of Ayushman Bharat insurance to 500 million beneficiaries in India, and increasing adoption of neuromodulation devices in Japan and South Korea. Europe is the second largest market with a share of over USD 25.10 billion in 2025, driven by EU MDR regulatory harmonization and Germany’s pioneering DiGA digital therapies fast-track pathway.

Why Are These Companies Leading the Market?

MRFR identifies four structural characteristics that define category leaders in the Pain Management Market: pharmaceutical-device integration enabling multimodal analgesia delivery within a single commercial relationship; closed-loop neuromodulation technology differentiation with clinically validated superiority over open-loop predecessors; breadth of pain application coverage spanning neuropathic, nociceptive, cancer, and migraine indications; and platform economics anchored by proprietary AI dosing algorithms and digital therapeutic capabilities that generate recurring revenue beyond the initial device or drug sale.

Platform integration defines the top-ranked vendors. Pfizer Inc. operates the broadest chronic pain pharmaceutical portfolio among global incumbents, reporting FY2025 total revenues of USD 62.6 billion (10-K confirmed), and announced a USD 1.8 billion non-opioid sodium channel inhibitor licensing deal in January 2025. Abbott Laboratories commands the device segment through its Proclaim XR closed-loop spinal cord stimulator—cleared by the FDA in March 2025 with AI-adaptive algorithms—with FY2025 total net sales of USD 44.3 billion (Annual Report confirmed).

Medtronic plc operates the most comprehensive neuromodulation portfolio, with the Neuroscience Portfolio reaching USD 9.846 billion in FY2025 revenue (8-K confirmed) and Neuromodulation growing 11% organically. These structural positions compound over time because closed-loop algorithm intellectual property, payer coverage relationships, and implanting physician training ecosystems create high switching costs that reinforce first-mover advantage.

Top 10 Global Pain Management Companies — MRFR Rankings (2026)

MRFR has identified and profiled the following leading pain management companies globally, evaluated on the basis of revenue performance, market capitalisation, geographic presence, product breadth across pharmacological and device modalities, innovation strategy, and institutional client base. All revenue figures have been validated against official company filings as indicated.

*Rankings based on MRFR analysis of reported revenues, pipeline depth, and pain market-specific positioning. Revenue figures sourced from official company filings (10-K, 8-K, 20-F, ARS) as cited. Pain market share estimates are MRFR analytical calculations and do not represent company-disclosed segment data.

Detailed Company Profiles

Pfizer Inc. | NYSE: PFE | New York, New York, USA

Pfizer Inc. holds the largest pharmaceutical revenue exposure to the Pain Management Market among globally listed companies, anchored by its Lyrica (pregabalin) chronic pain franchise and a diversified analgesic portfolio that spans opioid formulations, non-narcotic analgesics, and biosimilar versions of reference biologics. Pfizer operates across 175+ countries with more than 88,000 employees and reported FY2025 total revenues of USD 62.6 billion (confirmed via Form 10-K filed with the SEC), reflecting a 2% decrease from FY2024's USD 63.6 billion, with 6% operational revenue growth excluding COVID-19 products. Explore Pfizer's pain portfolio at pfizer.com/products/therapy-areas/pain.

Johnson & Johnson | NYSE: JNJ | New Brunswick, New Jersey, USA

Johnson & Johnson addresses the Pain Management Market through its integrated MedTech and Innovative Medicine segments. The company reported FY2025 total sales of USD 94.2 billion (+6.0% vs FY2024), confirmed via its Q4 & Full-Year 2025 earnings release and Annual Report to Shareholders. The MedTech segment delivered USD 33.8 billion in FY2025 revenue (operational growth +5.4%), with DePuy Synthes anchoring its interventional pain procedures commercial strategy through spine surgery systems and related devices. The Innovative Medicine segment reported USD 60.4 billion in FY2025 revenues, with neuroscience including pain-adjacent indications among ongoing R&D investment areas. Visit jnj.com/medtech/depuy-synthes for device pain management solutions.

Abbott Laboratories | NYSE: ABT | Abbott Park, Illinois, USA

Abbott Laboratories is the global leader in implantable neuromodulation devices for chronic pain management, operating through its Neuromodulation business unit developing and commercialising the Proclaim family of spinal cord stimulators (SCS), dorsal root ganglion (DRG) stimulation systems, and BurstDR sub-perception therapy. Abbott operates across 160+ countries with approximately 115,000 employees and reported FY2025 total net sales of USD 44.3 billion (confirmed via FY2025 Annual Report), representing a 5.7% increase from FY2024's USD 42.0 billion. Explore Abbott's neuromodulation portfolio at abbott.com/neuromodulation.

Medtronic plc | NYSE: MDT | Dublin, Ireland

Medtronic plc operates the most comprehensive neuromodulation and interventional pain procedures portfolio in the global Pain Management Market, spanning the Inceptiv closed-loop rechargeable spinal cord stimulator, the Intellis drug delivery pump for intrathecal analgesic delivery, deep brain stimulators, and the AiBLE ecosystem of AI-enabled spine surgery enabling technologies. Medtronic's Neuroscience Portfolio—encompassing Cranial & Spinal Technologies, Specialty Therapies, and Neuromodulation divisions—generated USD 9.846 billion in FY2025 (fiscal year ended April 25, 2025), confirmed via Medtronic's Q4 FY2025 earnings release (8-K). Total FY2025 worldwide revenue was USD 33.537 billion (+3.6% reported, +4.9% organic). Visit medtronic.com for pain management solutions.

Novartis AG | SIX: NOVN | Basel, Switzerland

Novartis AG participates in the Pain Management Market principally through its migraine and pain neuroscience pharmaceutical franchise, anchored by Aimovig (erenumab)—the first approved CGRP receptor antagonist for migraine prevention—and a pipeline of next-generation CGRP-pathway assets targeting episodic and chronic migraine, cluster headache, and pain-related inflammatory conditions. Novartis operates across 155+ countries with approximately 78,000 employees and reported FY2025 net sales of USD 54.5 billion (+8% in USD and constant currency), confirmed via the Novartis Q4 and Full Year 2025 Condensed Financial Report (6-K). Core operating income margin reached 40.1% for the first time. Explore Novartis's pain neuroscience pipeline at novartis.com/research-development/pipeline.

Teva Pharmaceutical Industries | NYSE: TEVA | Tel Aviv, Israel

Teva Pharmaceutical Industries participates in the Pain Management Market across two complementary strategic dimensions: its branded migraine biologic Ajovy (fremanezumab) competing directly in the CGRP inhibitor segment, and its position as the world's largest generic pharmaceutical manufacturer, providing scale in the supply of generic opioid analgesic formulations, NSAIDs, gabapentinoids, and non-narcotic analgesics globally. Teva operates across 60+ countries with approximately 37,000 employees. Teva's FY2025 revenues were USD 17.3 billion (+4% vs FY2024's USD 16.5 billion), confirmed via Teva's FY2025 Form 10-K filed with the SEC. Visit teva.com/our-medicines for Teva's full pain medicine portfolio.

Boston Scientific Corporation | NYSE: BSX | Marlborough, Massachusetts, USA

Boston Scientific is a global medical device leader whose Neuromodulation business unit designs and commercialises the WaveWriter Alpha spinal cord stimulation (SCS) system—offering rechargeable and recharge-free configurations, full-body MRI access, and the proprietary FAST AutoDose therapy—alongside the Intracept Intraosseous Nerve Ablation System for vertebrogenic low back pain. The company operates across 130+ countries and reported FY2025 total net sales of USD 20.1 billion (+19.9% vs FY2024's USD 16.747 billion), confirmed via the Boston Scientific Q4 and Full Year 2025 earnings release. Explore Boston Scientific's pain management portfolio at bostonscientific.com.

Eli Lilly and Company | NYSE: LLY | Indianapolis, Indiana, USA

Eli Lilly and Company participates in the Pain Management Market primarily through its Emgality (galcanezumab) CGRP monoclonal antibody franchise for migraine prevention and episodic cluster headache, and a growing pain neuroscience pipeline following the acquisition of SiteOne Therapeutics for Nav1.7/Nav1.8 sodium channel inhibitor programs targeting neuropathic and inflammatory pain. Lilly operates across 125+ countries with approximately 45,000 employees. FY2025 total revenues reached USD 65.2 billion (+45% vs FY2024's USD 45.0 billion), confirmed via Lilly's FY2025 10-K and Q4 2025 earnings release—driven principally by volume growth from Mounjaro and Zepbound. Visit lilly.com/our-medicines for Emgality and pain pipeline information.

Nevro Corp. (acquired by Globus Medical) | NYSE: GMED | Redwood City, California, USA

Nevro Corp. was an independent global medical device company specialising in high-frequency (10 kHz) spinal cord stimulation—the Senza HFX platform—which delivers paresthesia-free chronic pain relief validated through its landmark SENZA-PDN randomised controlled trial for painful diabetic neuropathy (PDN). Nevro reported FY2024 worldwide revenue of USD 408.5 million before its acquisition. Globus Medical announced the acquisition of Nevro Corp. for approximately USD 250 million in total equity value (USD 5.85 per share) in February 2025 and completed the transaction in April 2025, creating a combined entity with 2025 projected net sales of USD 2.80–2.90 billion. Visit globusmedical.com/neuromodulation for HFX platform updates.

Haleon plc | LSE: HLN | Weybridge, United Kingdom

Haleon plc is the world's largest dedicated consumer healthcare company, with a Pain Management Market position anchored by three globally recognised OTC analgesic brands: Advil (ibuprofen), Voltaren (diclofenac topical), and Panadol (paracetamol)—serving hundreds of millions of pain self-care occasions annually across 100+ countries. Haleon was demerged from GSK in 2022 and operates independently with approximately 24,000 employees. Haleon reported FY2025 total revenue of GBP 11.0 billion (confirmed via FY2025 20-F and full-year results release), with Pain Relief category revenue of GBP 2.6 billion in FY2025 (confirmed via FY2025 20-F Finance Review). Explore Haleon's portfolio at haleon.com/brands.

M&A Activity Tracker (2023–2026)

The Pain Management Market has experienced accelerating consolidation as device companies acquire neuromodulation and radiofrequency ablation capabilities, pharmaceutical companies license non-opioid molecular assets to replace opioid-dependent revenue, and private equity deploys capital into digital therapeutics and ambulatory pain care platforms. Market Research Future tracks the following verified transactions:

Key Trend: MRFR analysis identifies the non-opioid molecular licensing wave and closed-loop neuromodulation platform consolidation as the two dominant M&A themes in 2024–2026, with strategic acquirers paying premium valuations for assets that address regulatory pressure on opioid analgesic treatment while capturing the fastest-growing device and digital therapeutic segments of the Pain Management Market.

R&D Investment & Innovation Signals

R&D investment across the Pain Management Market has accelerated materially in 2024–2026 as pharmaceutical companies race to develop non-addictive analgesic alternatives and device companies invest in AI algorithms, wireless connectivity, and MRI-safe electrode materials. Market Research Future tracks the following verified 2024–2026 R&D and innovation signals from official company sources:

• Pfizer licensed a non-opioid sodium channel inhibitor targeting Nav1.8 receptors in a January 2025 transaction valued at USD 1.8 billion, representing the largest single non-opioid pain licensing commitment by a major pharmaceutical company in the post-opioid litigation era and signalling Pfizer's strategic redirection toward peripheral pain neuroscience.
• Abbott received FDA 510(k) clearance in March 2025 for the Proclaim XR closed-loop SCS system incorporating AI-adaptive algorithms that autonomously optimise electrode stimulation parameters based on real-time patient posture, activity level, and spinal cord response signals.
• Medtronic's Inceptiv closed-loop spinal cord stimulator—approved by the FDA in April 2024 as the first ECAP-sensing SCS system—drove low-double-digit (11%) Neuromodulation revenue growth in FY2025 (confirmed via Medtronic FY2025 8-K), validating the commercial impact of closed-loop pain device technology.
• Boston Scientific published 3.6-year sustained efficacy data from the FAST AutoDose real-world multicentre study in 2025, demonstrating a mean 6.1-point pain score reduction sustained over the longest published follow-up period for WaveWriter Alpha SCS sub-perception therapy, providing long-term payer evidence for chronic pain formulary inclusion.